<DOC>
	<DOCNO>NCT00700180</DOCNO>
	<brief_summary>This study explore correlation biomarkers response rate , overall efficacy safety , Avastin combination carboplatin-based chemotherapy patient advanced recurrent non-squamous non-small cell lung cancer . Patients randomize one 2 group , receive either Avastin 7.5mg/kg iv day 1 3 week cycle , Avastin 15mg/kg iv day 1 3 week cycle ; patient also receive treatment carboplatin either gemcitabine paclitaxel maximum 6 cycle . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Carboplatin-Based Chemotherapy Patients With Advanced Recurrent Non-Squamous Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; locally advance metastatic recurrent nonsquamous nonsmall cell lung cancer ( NSCLC ) ; &gt; =1 measurable tumor lesion ; ECOG performance status 01. prior chemotherapy treatment another systemic anticancer agent ; evidence CNS metastases ; history grade 2 high hemoptysis ; evidence tumor invade abut major blood vessel ; malignancy NSCLC within 5 year prior randomization , adequately treat cancer situ cervix , basal squamous cell skin cancer , localize prostate cancer DCIS ; clinically significant cardiovascular disease ; current recent use aspirin ( &gt; 325mg/day ) full dose anticoagulant thrombolytic agent therapeutic purpose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>